在急性白血病中对2'-脱氧化素的治疗选择性和反应预测
Lancet (London, England)
|December 5, 1981
概括
腺脱氨酶抑制剂2'-脱氧型素 (dCF) 在治疗急性淋巴细胞白血病 (Thy-ALL) 中表现有前途,12名患者中有7名患者实现完全缓解. 还注意到了响应预测和不良影响.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 常规化疗在耐火性急性白血病中经常失败.
- 氨酸脱氨酶 (ADA) 是 purin代谢中的关键酶,其抑制是一种潜在的治疗策略.
研究的目的:
- 评估2 - - 脱氧化菌素 (dCF),一种腺氨酸脱氨酶抑制剂,在急性白血病患者中对标准治疗不耐药的疗效.
- 为了确定对dCF治疗反应的预测因素.
- 为了记录与dCF治疗相关的不良影响.
主要方法:
- 十七名患有耐火性急性白血病的患者接受了dCF治疗.
- 患者根据白血病表型 (胸腺 vs. 其他) 进行了分层.
- 在体外研究中评估了细胞核酸的变化,以预测反应.
主要成果:
- 在12名胸膜急性淋巴细胞白血病 (Thy-ALL) 患者中,有7名患者实现了完全缓解.
- 另外两名Thy-ALL患者表现出部分反应;三名耐药.
- 五名患有其他急性白血病表型的患者表现出疾病进展.
- 和肝功能障碍,结膜炎和血液溶解是主要的不良影响.
结论:
- 2 -deoxycoformycin在一组耐火性Thy-ALL.患者中显示出显著的疗效.
- 在体外核酸水平分析可以预测dCF反应.
- 治疗dCF与可管理但显著的不良影响有关,需要仔细监测.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


